X-Biotix Therapeutics, Inc. Secures $7 million in Series A FinancingAnnounces Key Additions to Board of Directors and Senior Management
WALTHAM, Mass., April 24, 2018-- X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of novel small molecule antibiotic scaffolds targeting multi-drug-resistant (MDR) Gram-negative pathogens, announced that the company has secured $7 million in a Series A financing from a group of private investors. Proceeds of the financing will enable X-Biotix to advance its pipeline of novel antibiotic candidates targeting a wide range of biological targets in essential pathways of Gram-negative bacterial cells.